Pyxis Oncology, Inc. (NASDAQ:PYXS) Short Interest Update

Pyxis Oncology, Inc. (NASDAQ:PYXS) was the recipient of a large increase in short interest during the month of July. As of July 15th, there was short interest totalling 3,520,000 shares, an increase of 52.4% from the June 30th total of 2,310,000 shares. Based on an average daily volume of 578,900 shares, the days-to-cover ratio is presently 6.1 days. Approximately 7.4% of the company’s shares are sold short.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. HC Wainwright restated a “buy” rating and set a $7.00 price target on shares of Pyxis Oncology in a report on Thursday, May 16th. Jefferies Financial Group restated a “buy” rating and set a $10.00 price target on shares of Pyxis Oncology in a report on Tuesday, May 7th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Pyxis Oncology currently has a consensus rating of “Buy” and a consensus price target of $8.80.

Pyxis Oncology Stock Performance

Shares of PYXS stock traded up $0.03 during trading hours on Friday, hitting $3.88. 320,243 shares of the company were exchanged, compared to its average volume of 930,428. The firm has a market cap of $228.49 million, a P/E ratio of -2.85 and a beta of 1.28. Pyxis Oncology has a fifty-two week low of $1.35 and a fifty-two week high of $6.85. The company has a 50 day simple moving average of $3.50 and a two-hundred day simple moving average of $4.15.

Pyxis Oncology (NASDAQ:PYXS) last announced its quarterly earnings data on Saturday, May 11th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.19. The company had revenue of $16.15 million for the quarter, compared to analyst estimates of $4.25 million. As a group, sell-side analysts expect that Pyxis Oncology will post -1.09 EPS for the current fiscal year.

Institutional Trading of Pyxis Oncology

Several large investors have recently modified their holdings of the stock. Fullcircle Wealth LLC acquired a new stake in shares of Pyxis Oncology during the 2nd quarter worth approximately $40,000. SG Americas Securities LLC acquired a new stake in shares of Pyxis Oncology during the 1st quarter worth approximately $59,000. Cetera Advisors LLC acquired a new stake in Pyxis Oncology in the 1st quarter valued at $100,000. Cable Car Capital LLC acquired a new stake in Pyxis Oncology in the 4th quarter valued at $111,000. Finally, Susquehanna Fundamental Investments LLC acquired a new stake in Pyxis Oncology in the 1st quarter valued at $351,000. Institutional investors and hedge funds own 39.09% of the company’s stock.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.